hugbu schreef op 24 maart 2011 19:22:
Ik ook ....
Maar 't is eigenlijk niet echt duidelijk in het volgende :
Uit 'partnerships"
Our partnering strategy is to establish collaborations with major pharmaceutical and biotechnology companies to support development of internal programs through milestone payments and downstream royalties.
.......
GlaxoSmithKline
June 2006, Galapagos signed a broad alliance with GSK to discover and develop breakthrough medicines in osteoarthritis.
This multi-target, multi-year alliance runs from target discovery through to delivery of a clinical proof of concept. In June 2007, the scope of the alliance was expanded to include up to two drug discovery programs on selected GSK drug targets. In December 2008, Galapagos announced that the alliance was further expanded to include two additional drug targets. In December 2009, the alliance was again expanded to include additional drug discovery programs based on novel drug target GT622. Based on these expansions,
the alliance is now worth more than €200 million in milestones, plus up to double-digit royalties.In December 2007, GSK and Galapagos entered a strategic alliance to develop novel antibacterial and antiviral therapeutics. Galapagos is responsible for the discovery and development of natural product small molecule drug candidates through to clinical Proof of Concept, at which point GSK will have exclusive option to license each compound for further development and commercialization on a worldwide basis. The alliance utilizes the natural product compound collection and chemistry capabilities of BioFocus DPI, Galapagos’ services division. In January 2009, the alliance in antibacterials and antivirals was expanded to include three more discovery targets.